Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1998;98:211-216

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by John, S.
Right arrow Articles by Schmieder, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by John, S.
Right arrow Articles by Schmieder, R. E.

(Circulation. 1998;98:211-216.)
© 1998 American Heart Association, Inc.


Clinical Investigation and Reports

Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients

A Randomized, Placebo-Controlled, Double-blind Study

Stefan John, MD; Markus Schlaich, MD; Matthias Langenfeld, MD; Horst Weihprecht, MD; Gerd Schmitz, MD; Gottfried Weidinger, MD; ; Roland E. Schmieder, MD

From Department of Medicine IV (S.J., M.S., M.L., H.W., G.W., R.E.S.), University of Erlangen-Nürnberg, Klinikum Nürnberg-Süd, Nürnberg, Germany, and Department of Clinical Chemistry and Laboratory Medicine (G.S.), University of Regensburg, Germany.

Background—Impaired endothelium-dependent vasodilation is an early sign of atherosclerosis in hypercholesterolemic patients. We hypothesized that lipid-lowering therapy can improve endothelial function and that this effect is mainly mediated by increased bioavailability of nitric oxide (NO).

Methods and Results—In a randomized, double-blind, placebo-controlled trial, we studied 29 patients (age, 50±12 years) with hypercholesterolemia (LDL cholesterol >=160 mg/dL) randomly assigned to receive either fluvastatin (40 mg twice daily; 17 patients) or placebo (12 patients). Forearm blood flow was measured by plethysmography before and after 24 weeks of treatment. Endothelium-dependent vasodilation was assessed by intra-arterial infusion of acetylcholine (ACh; 3, 12, 24, and 48 µg/min) and basal NO synthesis rate by intra-arterial infusion of NG-monomethyl-L-arginine (L-NMMA; 1, 2, and 4 µmol/min). Simultaneous intra-arterial infusion of L-NMMA (4 µmol/min) and ACh (12, 24, and 48 µg/min) was used to test whether any increase in endothelium-dependent vasodilation after lipid-lowering therapy could be blocked by this NO synthase inhibitor. Endothelium-dependent vasodilation improved significantly after 24 weeks of lipid-lowering therapy compared with before therapy (ACh 24 µg/min: 240±34% before versus 347±50% after therapy; P<=0.01) and placebo (changes between after and before therapy with ACh 24 µg/min: 108±39% for fluvastatin versus -26±32% for placebo; P<=0.05). This improvement in endothelium-dependent vasodilation could be blocked by simultaneous administration of L-NMMA (ACh 24 µg/min plus L-NMMA 4 µmol/min: 170±69% before versus 219±47% after treatment; P=NS).

Conclusions—Lipid-lowering therapy with fluvastatin can improve disturbed endothelial function in hypercholesterolemic patients compared with placebo. This improvement is mediated by increased bioavailability of NO.


Key Words: atherosclerosis • endothelium • blood flow • hypercholesterolemia • nitric oxide • vasodilation




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
V. Rudolph, T. K. Rudolph, F. J. Schopfer, G. Bonacci, D. Lau, K. Szocs, A. Klinke, T. Meinertz, B. A. Freeman, and S. Baldus
Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 324 - 331.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
M. Focardi, G. M. Dick, A. Picchi, C. Zhang, and W. M. Chilian
Restoration of coronary endothelial function in obese Zucker rats by a low-carbohydrate diet
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2093 - H2099.
[Abstract] [Full Text] [PDF]


Home page
Diabetes and Vascular Disease ResearchHome page
R. G Casey, M. Joyce, K. Moore, C. Thompson, P. Fitzgerald, and D. J Bouchier-Hayes
Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes
Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 53 - 61.
[Abstract] [PDF]


Home page
VASC ENDOVASCULAR SURGHome page
T. W. Rice and A. B. Lumsden
Optimal Medical Management of Peripheral Arterial Disease
Vascular and Endovascular Surgery, August 1, 2006; 40(4): 312 - 327.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
K. Douglas, P. G. O'Malley, and J. L. Jackson
Meta-Analysis: The Effect of Statins on Albuminuria
Ann Intern Med, July 18, 2006; 145(2): 117 - 124.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Al-Benna, C. A. Hamilton, J. D. McClure, P. N. Rogers, G. A. Berg, I. Ford, C. Delles, and A. F. Dominiczak
Low-Density Lipoprotein Cholesterol Determines Oxidative Stress and Endothelial Dysfunction in Saphenous Veins From Patients With Coronary Artery Disease
Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 218 - 223.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. G. Herman and S. Moncada
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J.-H. Bae, E. Bassenge, K.-Y. Kim, Y.-C. Synn, k.-R. Park, and M. Schwemmer
Effects of Low-Dose Atorvastatin on Vascular Responses in Patients Undergoing Percutaneous Coronary Intervention With Stenting
Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 185 - 192.
[Abstract] [PDF]


Home page
CirculationHome page
J. Davignon and P. Ganz
Role of Endothelial Dysfunction in Atherosclerosis
Circulation, June 15, 2004; 109(23_suppl_1): III-27 - III-32.
[Abstract] [Full Text]


Home page
J. Am. Soc. Nephrol.Home page
C. R. Wolfram Kuhlmann, C. Gast, F. Li, M. Schafer, H. Tillmanns, B. Waldecker, and J. Wiecha
Cerivastatin Activates Endothelial Calcium-Activated Potassium Channels and Thereby Modulates Endothelial Nitric Oxide Production and Cell Proliferation
J. Am. Soc. Nephrol., April 1, 2004; 15(4): 868 - 875.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas
Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review
Ann Intern Med, October 21, 2003; 139(8): 670 - 682.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Galle and S. Seibold
Has the time come to use antioxidant therapy in uraemic patients?
Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1452 - 1455.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. Binggeli, L. E. Spieker, R. Corti, I. Sudano, V. Stojanovic, D. Hayoz, T. F. Luscher, and G. Noll
Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring test of endothelial dysfunction for clinical practice?
J. Am. Coll. Cardiol., July 2, 2003; 42(1): 71 - 77.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. H. Fleischmann, M. P. Schlaich, B. M. W. Schmidt, S. Oehmer, and R. E. Schmieder
Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics
Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1758 - 1765.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Sanada, Y. Higashi, K. Nakagawa, M. Tsuda, I. Kodama, M. Kimura, K. Chayama, and K. Ohama
Hormone Replacement Effects on Endothelial Function Measured in the Forearm Resistance Artery in Normocholesterolemic and Hypercholesterolemic Postmenopausal Women
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4634 - 4641.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. E. Ferrier, M. H. Muhlmann, J.-P. Baguet, J. D. Cameron, G. L. Jennings, A. M. Dart, and B. A. Kingwell
Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension
J. Am. Coll. Cardiol., March 20, 2002; 39(6): 1020 - 1025.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. C. B. Tan, W. S. Chow, S. C. F. Tam, V. H. G. Ai, C. H. L. Lam, and K. S. L. Lam
Atorvastatin Lowers C-Reactive Protein and Improves Endothelium-Dependent Vasodilation in Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 563 - 568.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. Sterzer, F. Meintzschel, A. Rosler, H. Lanfermann, H. Steinmetz, and M. Sitzer
Pravastatin Improves Cerebral Vasomotor Reactivity in Patients With Subcortical Small-Vessel Disease
Stroke, December 1, 2001; 32(12): 2817 - 2820.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Imamura, S. Biro, T. Kihara, S. Yoshifuku, K. Takasaki, Y. Otsuji, S. Minagoe, Y. Toyama, and C. Tei
Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1083 - 1088.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Asberg, A. Hartmann, E. Fjeldsa, and H. Holdaas
Atorvastatin improves endothelial function in renal-transplant recipients
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1920 - 1924.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. W Wilmink, M. B Twickler, J. D. Banga, G. M Dallinga-Thie, H. Eeltink, D.W. Erkelens, T. J Rabelink, and E. S Stroes
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles
Cardiovasc Res, June 1, 2001; 50(3): 577 - 582.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Martinez-Gonzalez, B. Raposo, C. Rodriguez, and L. Badimon
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Prevents Endothelial NO Synthase Downregulation by Atherogenic Levels of Native LDLs : Balance Between Transcriptional and Posttranscriptional Regulation
Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 804 - 809.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. John, C. Delles, J. Jacobi, M. P. Schlaich, M. Schneider, G. Schmitz, and R. E. Schmieder
Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks
J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1351 - 1358.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Babaei, P. Picard, A. Ravandi, J. C. Monge, T. C. Lee, P. Cernacek, and D. J. Stewart
Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation
Cardiovasc Res, October 1, 2000; 48(1): 158 - 167.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. K. Koh
Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability
Cardiovasc Res, September 1, 2000; 47(4): 648 - 657.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. H. Wagner, T. Kohler, U. Ruckschloss, I. Just, and M. Hecker
Improvement of Nitric Oxide-Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion Formation
Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 61 - 69.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
W. M. Landau
Is Cholesterol a Risk Factor for Stroke?: No
Arch Neurol, December 1, 1999; 56(12): 1521 - 1524.
[Full Text] [PDF]


Home page
CirculationHome page
D. Baller, G. Notohamiprodjo, U. Gleichmann, J. Holzinger, R. Weise, and J. Lehmann
Improvement in Coronary Flow Reserve Determined by Positron Emission Tomography After 6 Months of Cholesterol-Lowering Therapy in Patients With Early Stages of Coronary Atherosclerosis
Circulation, June 8, 1999; 99(22): 2871 - 2875.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R A Archbold and A D Timmis
Cholesterol lowering and coronary artery disease: mechanisms of risk reduction
Heart, December 1, 1998; 80(6): 543 - 547.
[Full Text]